Last update 21 Nov 2024

Ramucirumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Ramucirumab (Genetical Recombination), Ramucirumab (USAN), Ramucirumab (genetical recombination) (JAN)
+ [11]
Target
Mechanism
VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Colorectal Cancer
NO
19 Dec 2014
Colorectal Cancer
IS
19 Dec 2014
Colorectal Cancer
LI
19 Dec 2014
Colorectal Cancer
EU
19 Dec 2014
Hepatocellular Carcinoma
NO
19 Dec 2014
Hepatocellular Carcinoma
LI
19 Dec 2014
Hepatocellular Carcinoma
IS
19 Dec 2014
Hepatocellular Carcinoma
EU
19 Dec 2014
Malignant neoplasm of gastro-oesophageal junction
IS
19 Dec 2014
Metastatic Colorectal Carcinoma
LI
19 Dec 2014
Metastatic Colorectal Carcinoma
EU
19 Dec 2014
Metastatic Colorectal Carcinoma
NO
19 Dec 2014
Metastatic Colorectal Carcinoma
IS
19 Dec 2014
Non-Small Cell Lung Cancer
LI
19 Dec 2014
Non-Small Cell Lung Cancer
EU
19 Dec 2014
Non-Small Cell Lung Cancer
NO
19 Dec 2014
Non-Small Cell Lung Cancer
IS
19 Dec 2014
metastatic non-small cell lung cancer
US
12 Dec 2014
Gastroesophageal junction adenocarcinoma
US
21 Apr 2014
Stomach Cancer
US
21 Apr 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2-negative breast cancerPhase 2
BR
06 Aug 2008
HER2-negative breast cancerPhase 2
LB
06 Aug 2008
HER2-negative breast cancerPhase 2
KR
06 Aug 2008
HER2-negative breast cancerPhase 2
CA
06 Aug 2008
HER2-negative breast cancerPhase 2
TW
06 Aug 2008
HER2-negative breast cancerPhase 2
GB
06 Aug 2008
HER2-negative breast cancerPhase 2
IL
06 Aug 2008
HER2-negative breast cancerPhase 2
EG
06 Aug 2008
HER2-negative breast cancerPreclinical
RU
06 Aug 2008
HER2-negative breast cancerDiscovery
SK
06 Aug 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
139
(hznbqgqbbm) = ctwhzkccrw souifojiwq (fdaapbreul )
Positive
08 Oct 2024
(hznbqgqbbm) = efyfcefhed souifojiwq (fdaapbreul )
Phase 2
Metastatic Colorectal Carcinoma
Second line
RAS wild-type
92
Ramucirumab plus FOLFIRI
(kfqyncnqnq) = ujpkpdoeqv qwtultpkjr (oavegmvzwz, 49.3 - 66.2)
Positive
16 Sep 2024
Ramucirumab plus FOLFIRI
(early tumor shrinkage positive)
(hjknlbgihx) = ksvgmflfau fpwffnhjws (wclpzukbeg )
ESMO2024
ManualManual
Not Applicable
Non-Small Cell Lung Cancer
Third line | Second line
173
Docetaxel with Nintedanib (D+N)
(eahouyhfqq) = gqchkmwjwa rmbgwmzshx (xqcpnlxyng )
Negative
14 Sep 2024
(eahouyhfqq) = bngjrxrlag rmbgwmzshx (xqcpnlxyng )
Phase 2
122
FOLFIRI plus RAM
(hyacsmxcoh) = yqdvtaxzhw zofhwbzpis (nynzdurgqm, 26.8 - 36.5)
Negative
14 Sep 2024
8 cycles of FOLFOXIRI plus RAM followed by 5-FU/l-leucovorin plus RAM
(hyacsmxcoh) = trrvcvsdwk zofhwbzpis (nynzdurgqm, 21.9 - 31.2)
Phase 2
15
(wdnkvhsnxf) = ocemwuilqu xryhpupunx (huwqxcyepc, 5.4 - NE)
Positive
14 Sep 2024
Phase 2
45
(ggwagfomix) = jqotbrhryo frkfwzqhnk (abicagniyx )
Positive
13 Sep 2024
Phase 2/3
127
(dcyazmxedb) = vgvhtupplq chkmauwlor (ifjfhiwdop )
Positive
31 Jul 2024
(dcyazmxedb) = kdyugxvcka chkmauwlor (ifjfhiwdop )
Phase 1
175
gxvqvaozke(eqsdfjfcfc) = qghtxtbvby kjlcazqakg (idnidxveob, muutkarcsg - kryxsccxam)
-
31 Jul 2024
gxvqvaozke(eqsdfjfcfc) = gbgvtujepn kjlcazqakg (idnidxveob, jxmrfxgaey - wrjuivemup)
Phase 1/2
40
bqcbgteygl(ywrhdkdqng) = tbbadqjddb jndwarxfpb (oowtijwehl, 38 - 70)
Positive
01 Jul 2024
Phase 2
110
(wllltfxrfs) = mwqbrfoehe ozzmgnmpvk (vudxuranhr )
Positive
20 Jun 2024
(wllltfxrfs) = erjkvxhprz ozzmgnmpvk (vudxuranhr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free